A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety & efficacy of Certolizumab Pegol (CZP) as additional
medication to Methotrexate (MTX) in Chinese subjects with Rheumatoid Arthritis. 400 patients
will be randomized to receive either CZP + MTX or placebo + MTX. Anticipated time in the
study is about 32 weeks.